Milvexian for atrial fibrillation (LIBREXIA-AF)

LIBREXIA-AF is a non-inferiority trial of FXIa inhibitor milvexian vs apixaban in AF. The FXIa class has had setbacks: asundexian (BAYER OCEANIC-AF) failed for efficacy vs apixaban in 2023, raising class risk. Milvexian's Phase 2 AXIOMATIC-SSP was mixed. Beating/matching apixaban's established efficacy is a high bar. Primary completion ~2027, so readout timing adds uncertainty. Base rate for FXIa NI vs apixaban in AF is poor given class precedent.

The objective stroke/systemic embolism endpoint and long follow-up support reliable ascertainment, while active-not-recruiting status lowers enrollment risk. However, matching apixaban on efficacy is a demanding noninferiority test, and no supportive prior efficacy data or margin details are provided.

A Phase 3 active, completed-enrollment program with an objective stroke/systemic-embolism endpoint supports execution quality. However, matching apixaban on rare thromboembolic events is a demanding noninferiority bar, and the supplied record provides no sample size, margin, or prior efficacy evidence to reduce uncertainty.

Phase 3, active-not-recruiting status and a large, event-driven comparison against apixaban support meaningful execution credibility. The endpoint is clinically important and objective, but demonstrating at least comparable stroke/systemic-embolism prevention against an established anticoagulant is demanding, with long follow-up and material operational/disclosure uncertainty.

Phase 3 non-inferiority trial vs apixaban in AF with standard composite stroke/non-CNS SE endpoint; enrollment complete, long follow-up, experienced sponsor, no design red flags support modest >50% probability of demonstrating non-inferiority.

Factor XIa inhibitors have faced major setbacks in AFib, notably Bayer's asundexian failing its Phase 3 OCEANIC-AF trial due to inferior efficacy versus apixaban. While milvexian's dosing and pharmacology differ, class-wide concerns remain regarding whether FXIa inhibition can reliably match apixaban's high efficacy bar in stroke prevention, making non-inferiority a tough hurdle.

Phase‑3 non‑inferiority trial comparing milvexian to apixaban on a hard stroke/embolism endpoint. Robust endpoint, typical AF population, and Janssen’s strong execution suggest at least parity. Novel factor‑XI inhibition shows favorable safety, giving moderate confidence (~58%) of a positive result.

Milvexian (FXIa inhibitor) Phase 2 in AF showed efficacy numerically similar to apixaban but no clear advantage; some dose arms trended toward more bleeding. Apixaban is a strong, established DOAC comparator, making non-inferiority the realistic bar. FXIa class (abelacimab, others) has not consistently beaten DOACs, raising class-level risk. Active Not Recruiting suggests normal follow-up, but 451 days to readout leaves execution and event-rate risk. Meeting NI margin is plausible but not assured; superiority unlikely.